Published in Prostate on February 15, 2009
DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn (2009) 1.08
Promoter hypermethylation in prostate cancer. Cancer Control (2010) 0.99
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. PLoS One (2012) 0.85
GATA4 and DcR1 methylation in glioblastomas. Diagn Pathol (2013) 0.81
DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. Biomed Res Int (2015) 0.77
Applicability of the methylated CpG sites of paired box 5 (PAX5) promoter for prediction the prognosis of gastric cancer. Oncotarget (2014) 0.77
The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication. Comput Biol Chem (2016) 0.75
TNFRSF10C copy number variation is associated with metastatic colorectal cancer. J Gastrointest Oncol (2016) 0.75
Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites. Hum Mutat (2015) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Real-time PCR for mRNA quantitation. Biotechniques (2005) 7.80
Prostate cancer. N Engl J Med (2003) 5.91
Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity (1997) 3.33
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity (1997) 2.60
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
Identification and resolution of artifacts in bisulfite sequencing. Methods (2002) 2.27
Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene (1996) 2.21
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer (2006) 1.58
Retracted Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett (2006) 1.40
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer (2004) 1.32
Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res (1999) 1.32
Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res (2007) 1.10
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer (2005) 1.10
Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res (2002) 1.07
Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene (2003) 1.04
Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res (2007) 1.03
Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet (2006) 0.93
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics (2008) 0.90
Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai) (2006) 0.89
Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene (1999) 0.89
Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. Cancer Res (2005) 0.89
Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene (2006) 0.88
Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res (2006) 0.87
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer (2008) 0.87
Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer (2003) 0.82
Allelic loss on the short arm of chromosome 8 in oral squamous cell carcinoma. Oncol Rep (1999) 0.78
Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells. Int J Oncol (2002) 0.78
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Characterization of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3) ferroelectric crystal with enhanced phase transition temperatures. J Appl Phys (2008) 7.49
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol (2002) 4.27
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Electromechanical characterization of [Formula: see text] crystals as a function of crystallographic orientation and temperature. J Appl Phys (2009) 3.80
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell (2002) 3.71
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 3.68
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Complete set of material constants of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3)single crystal with morphotropic phase boundary composition. J Appl Phys (2009) 3.22
Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med (2012) 3.21
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Acetylation of Smc3 by Eco1 is required for S phase sister chromatid cohesion in both human and yeast. Mol Cell (2008) 3.01
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet (2012) 2.70
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet (2001) 2.61
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet (2013) 2.47
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Erratum: "A complete set of material properties of single domain 0.26Pb(In(12)Nb(12))O(3)-0.46Pb(Mg(13)Nb(23))O(3)-0.28PbTiO(3) single crystals" [Appl. Phys. Lett. 96, 012907 (2010)]. Appl Phys Lett (2010) 2.30
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Elastic, dielectric, and piezoelectric constants of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3) single crystal poled along [011](c). Appl Phys Lett (2010) 2.28
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27